TY - JOUR
T1 - Investigation of the strategies for targeting of the afterglow nanoparticles to tumor cells
AU - Rashidi, Leila Hossein
AU - Homayoni, Homa
AU - Zou, Xiaoju
AU - Liu, Li
AU - Chen, Wei
N1 - Funding Information:
We would like to acknowledge the support from the U.S. Army Medical Research Acquisition Activity (USAMRAA) under Contracts of W81XWH-10-1-0279 and W81XWH-10-1-0234 and the NSF and DHS joint ARI program ( 2008-DN-077-ARI016-05 , CBET-1039068 ). We thank Professor Kytai Nguyen for permitting us to use some of the instruments in her lab and for providing us EDTA, Professor Jer-Tsong Hsieh in UT Southwestern Medical Center and Professor Richard Timmons at UT Arlington, Department of Chemistry and Biochemistry, for providing us with R11 peptide and plasma coated NPs, respectively.
Publisher Copyright:
© 2015 Elsevier B.V.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Afterglow nanoparticles have been widely investigated as new agents for cancer imaging and as a light source for photodynamic activation for cancer treatment. For both applications, the targeting of the afterglow nanoparticles to tumor cells is an important and challenging issue. Here we report the strategies for targeting Sr3MgSi2O8:Eu2+,Dy3+ afterglow nanoparticles to tumor cells by conjugating with variety of targeting molecules such as folic acid, RGD peptide, and R-11 peptide. For folic acid targeting, experimental observations were conducted on PC-3 cells (folate receptor negative), MCF-7 (folate receptor positive), and KB cells (folate receptor positive) to compare the cellular uptake and confirm targeted delivery. For the cyclic RGDfK peptide, experiments were carried out on the integrin αvβ3 positive MDA-MB-231 breast cancer cell line and the integrin αvβ3 negative MCF-7 breast cancer cell lines in order to compare the cellular uptakes. As for R11-SH peptide, cellular uptake of the afterglow nanoparticles was observed on LNCaP and PC3 prostate cancer cell lines. All the observations showed that the cellular uptakes of the nanoparticles were enhanced by conjugation to variety of targeting molecules which are specific for breast and prostate cancer cells.
AB - Afterglow nanoparticles have been widely investigated as new agents for cancer imaging and as a light source for photodynamic activation for cancer treatment. For both applications, the targeting of the afterglow nanoparticles to tumor cells is an important and challenging issue. Here we report the strategies for targeting Sr3MgSi2O8:Eu2+,Dy3+ afterglow nanoparticles to tumor cells by conjugating with variety of targeting molecules such as folic acid, RGD peptide, and R-11 peptide. For folic acid targeting, experimental observations were conducted on PC-3 cells (folate receptor negative), MCF-7 (folate receptor positive), and KB cells (folate receptor positive) to compare the cellular uptake and confirm targeted delivery. For the cyclic RGDfK peptide, experiments were carried out on the integrin αvβ3 positive MDA-MB-231 breast cancer cell line and the integrin αvβ3 negative MCF-7 breast cancer cell lines in order to compare the cellular uptakes. As for R11-SH peptide, cellular uptake of the afterglow nanoparticles was observed on LNCaP and PC3 prostate cancer cell lines. All the observations showed that the cellular uptakes of the nanoparticles were enhanced by conjugation to variety of targeting molecules which are specific for breast and prostate cancer cells.
KW - Afterglow nanoparticles
KW - Biomolecules
KW - Cancer treatment
KW - Targeting
UR - http://www.scopus.com/inward/record.url?scp=84960795712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960795712&partnerID=8YFLogxK
U2 - 10.1016/j.pdpdt.2015.08.001
DO - 10.1016/j.pdpdt.2015.08.001
M3 - Article
C2 - 26253653
AN - SCOPUS:84960795712
SN - 1572-1000
VL - 13
SP - 244
EP - 254
JO - Photodiagnosis and Photodynamic Therapy
JF - Photodiagnosis and Photodynamic Therapy
ER -